RxAdvance
runs on Collaborative PBM Cloud™

Clinical Policy Title:	abrocitinib
Policy Number:	RxA.752
Drug(s) Applied:	Cibinqo™
Original Policy Date:	04/18/2022
Last Review Date:	12/11/2025
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. **Initial Approval Criteria**
   A. **Moderate to severe atopic dermatitis** (must meet all)**:**
      1. Diagnosis of moderate to severe atopic dermatitis;
      2. Member meets one of the following (a or b):
         a. ≥10% of the body surface area involvement;
         b. Baseline scoring atopic dermatitis (SCORAD) ≥25;
      3. Trial and failure with all of the following (a, b, and c):
         a. One medium to high potency topical corticosteroid or topical calcineurin inhibitor;
         b. Eucrisa or Opzelura.
         c. One systemic agent (ie. Adbry or Dupixent).

      Approval Duration
      All Lines of Business (except Medicare): 12 months

II. **Continued Therapy Approval**
   A. **Moderate to severe atopic dermatitis** (must meet all):
      1. Auto-approval based on lookback functionality within the past 120 days as a proxy for member responding positively to therapy.

      Approval Duration
      All Lines of Business (except Medicare): 12 months

References

1. David M Fleischer, MD; Jeremy Udkoff, MA, Atopic dermatitis: skin care and topical therapies. Seminar in cutaneous medicine and surgery, September 2017, Vol 36, No. 3. Available at: https://nationaleczema.org/wp-content/uploads/2018/03/258887_eprint4.pdf. Accessed August 28, 2024.
2. Dermatitis. Topical calcineurin inhibitors | dermnet nz. Available at: https://dermnetnz.org/cme/dermatitis/topical-calcineurin-inhibitors. Accessed August 28, 2024.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	03/08/2022	04/18/2022
1. Initial Approval Criteria, I. A.2: Updated age criteria	3/28/2023	04/13/2023

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

© 2025 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.

RxAdvance
runs on Collaborative PBM Cloud™

from Age ≥18 years to Age ≥12 years; 2. References were reviewed and updated.		
Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed: 1. Removed age requirement. 2. Removed trial and failure requirement for phototherapy. 3. Removed trial and failure criteria for Dupixent. 4. Removed coadministration criteria. 5. Removed dosing criteria. 6. Removed 'positive response to therapy' criteria from reauthorization. 7. References were reviewed and updated.	02/01/2024	02/01/2024
Policy was reviewed: 1. Removed prescriber restrictions. 2. Updated Continued therapy approval with auto-approval based on lookback functionality within the past 120 days. 3. Updated approval duration verbiage. 4. References were reviewed and updated.	08/28/2024	9/13/2024
Policy was reviewed: 1. Added trial and failure with 2 topicals 2. Added trial and failure with Eucrisa or Opzlura	6/19/2025	6/19/2025
Policy reviewed.	12/11/2025	12/11/2025

© 2025 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.